Orthomyxoviridae (e.g., Influenza Virus, Fowl Plague Virus, Etc.) Patents (Class 424/209.1)
-
Publication number: 20090028904Abstract: A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.Type: ApplicationFiled: April 23, 2008Publication date: January 29, 2009Applicant: BioDelivery Sciences International, Inc.Inventors: Leila Zarif, Tuo Jin, Ignacio Segarra, Raphael J. Mannino
-
Publication number: 20090022762Abstract: Polyvalent influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these polyvalent VLPs as well as methods of making and using these VLPs.Type: ApplicationFiled: April 30, 2007Publication date: January 22, 2009Applicant: Techno Vax, Inc.Inventors: Jose M. Galarza, Demetrius Matassov
-
Publication number: 20090017066Abstract: The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza.Type: ApplicationFiled: May 27, 2008Publication date: January 15, 2009Inventors: Gale Smith, Peter Pushko, Kutub Mahmood, Bin Zhao
-
Publication number: 20090017067Abstract: Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an oil phase in the presence of an emulsifier.Type: ApplicationFiled: June 19, 2008Publication date: January 15, 2009Applicant: WyethInventors: Evan James Diehl, David Leon Lutz, Jeffrey Harold Rodenberg, Mahesh Kumar
-
Publication number: 20090012494Abstract: The present invention relates to methods for intradermally delivering one or more biologically active agents such as vaccines and therapeutic agents into the dermis layer of the skin of a subject to obtain systemic delivery or an immune response using a microneedle drug delivery device containing the agent to be delivered. The methods employ a microneedle device with a row of hollow microneedles. The microneedles penetrate the skin of the subject and assume an anchored state in which the microneedles are anchored in the skin and project laterally from the device. A pivotal motion is then performed with the device so that the skin in which the microneedles are engaged is lifted above the initial plane of the surface of the skin while the biologically active agent is delivered. The methods of the invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery routes, facilitating dose sparing.Type: ApplicationFiled: November 29, 2007Publication date: January 8, 2009Applicant: NanoPass Technologies Ltd.Inventors: Yehoshua Yeshurun, Yotam Levin, Yotam Almagor, Gilad Lavi, Meir Hefetz, Yoel Sefi, Richard Ian Catchpole
-
Publication number: 20090010964Abstract: The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5?3], decosahexaenoic acid [C22: 6?3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.Type: ApplicationFiled: August 3, 2006Publication date: January 8, 2009Inventors: Anne Grobler, Abraham Frederik Kotze
-
Publication number: 20090010962Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: June 1, 2005Publication date: January 8, 2009Applicants: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THE UNITED STATED OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Patent number: 7468187Abstract: The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4 , with the proviso that the amino acids at positions 94 and 233 are identical to SEQ ID NO: 4; a composition comprising attenuated or inactivated virus; isolated or purified HA, NM, NP, M1 , NS1 , PA, PB1 , and PB2 proteins and fragments thereof and compositions comprising same or nucleic acids, optionally as part of a vector, encoding same; and a method of inducing an immune response to canine influenza virus in an animal comprising administering to the animal an aforementioned composition.Type: GrantFiled: October 5, 2006Date of Patent: December 23, 2008Assignee: Iowa State University Research Foundation, Inc.Inventors: Kyoung-Jin Yoon, Vickie Cooper
-
Publication number: 20080311106Abstract: The invention provides a product which comprises a C4bp core protein and a monomeric antigen, desirably in the form of a fusion protein. Monomeric antigens include malarial and influenza antigens. The C4bp core protein provides for assembly of multimeric complexes of the monomeric antigen, or mixtures thereof. The complexes are useful as vaccines.Type: ApplicationFiled: August 12, 2004Publication date: December 18, 2008Applicant: IMAXIOInventor: Fergal Hill
-
Patent number: 7465456Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.Type: GrantFiled: May 20, 2005Date of Patent: December 16, 2008Assignee: MedImmune, LLCInventors: Erich Hoffmann, Hong Jin, Bin Lu, Gregory Duke, George Kemble, Zhongying Chen
-
Publication number: 20080299151Abstract: Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and/or RNA encoding Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and/or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed.Type: ApplicationFiled: May 30, 2008Publication date: December 4, 2008Applicant: Statens Serum InstitutInventor: Anders Fomsgaard
-
Publication number: 20080286307Abstract: The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual temperature cultivation process, high titer and improved purity can be obtained.Type: ApplicationFiled: April 30, 2008Publication date: November 20, 2008Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt
-
Publication number: 20080279891Abstract: The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject.Type: ApplicationFiled: July 8, 2005Publication date: November 13, 2008Inventors: Robert E. Johnston, Joseph M. Thompson
-
Publication number: 20080279926Abstract: An immunogenic composition in a dose volume suitable for human use comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 ?g.Type: ApplicationFiled: December 12, 2006Publication date: November 13, 2008Inventor: Pierre Vandepapeliere
-
Patent number: 7449188Abstract: The present invention relates to a chimeric protein comprising an antigen and an oligomerisation domain. The present invention relates further to recombinant oligomeric protein complexes comprising said chimeric protein and the use thereof for the manufacture of a vaccine.Type: GrantFiled: January 18, 2002Date of Patent: November 11, 2008Assignee: Vlaams Interuniversitair Instituut Voor BiotechnologieInventors: Marina De Filette, Tom Maria Deroo, Walter Fiers, Marleen Maras, Willy Alfons Min Jou
-
Publication number: 20080274141Abstract: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the process or constituents thereof.Type: ApplicationFiled: June 26, 2008Publication date: November 6, 2008Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KGInventors: Albrecht Groner, Jurgen Vorlop
-
Patent number: 7442527Abstract: The present invention relates, in general, to a screening method for identifying novel viral proteins with interferon antagonizing function using a transfection-based assay, and the use of such proteins in isolating various types of attenuated viruses for the development of vaccine and pharmaceutical formulations. The invention also relates to the use of viral interferon antagonists in screening assays to identify potential anti-viral agents. The invention further relates to protocols utilizing interferon antagonists, e.g., NS1, to enhance gene therapy or DNA vaccination based on their ability to increase gene expression.Type: GrantFiled: March 14, 2006Date of Patent: October 28, 2008Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter M. Palese, Adolfo Garcia-Sastre, Christopher Basler
-
Publication number: 20080260764Abstract: The present invention provides isolated influenza peptides and nucleic acid sequences and methods of identifying said influenza peptides and nucleic acid sequences having a pattern of substitution of amino acids or nucleic acids in highly conserved Replikin and Replikin Scaffold sequences that is predictive of rapid replication and virulence. Methods of predicting virulence in emerging influenza strains are provided comprising identifying peptides and nucleic acid sequences having the predictive pattern of substitution.Type: ApplicationFiled: May 30, 2007Publication date: October 23, 2008Inventors: Samuel Bogoch, Elenore S. Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi
-
Patent number: 7438919Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.Type: GrantFiled: March 6, 2007Date of Patent: October 21, 2008Assignee: The University of Pittsburgh -- of the Commonwealth System of Higher EducationInventors: Patricia W. Dowling, Julius S. Youngner
-
Publication number: 20080254067Abstract: The present invention relates to a commercial-scale process for the production of influenza virus or antigens for prophylactic, diagnostic, immunotherapeutic or therapeutic purposes. Particularly, the invention provides a Madin-Darby Canine Kidney (MDCK)-derived, cell line and a cell culture-based process for the production of an influenza vaccine and more particularly, a human vaccine comprising influenza types A and B.Type: ApplicationFiled: May 20, 2005Publication date: October 16, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Pierre Trepanier, Robert Dugre, Tom Hassell
-
Patent number: 7432045Abstract: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.Type: GrantFiled: December 1, 2004Date of Patent: October 7, 2008Assignee: Wisconsin Alumni Research FoundationInventors: Curtis R. Brandt, Hermann Bultmann
-
Publication number: 20080241184Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: ApplicationFiled: January 28, 2008Publication date: October 2, 2008Inventors: Jules Maarten Minke, Kemal Karaca, Jiansheng Yao
-
Publication number: 20080233142Abstract: A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.Type: ApplicationFiled: May 24, 2007Publication date: September 25, 2008Inventors: Gregory M. Glenn, Carl Alving
-
Publication number: 20080233149Abstract: The present invention relates to the use of erythropoietin (EPO) for enhancing immune responses and for the treatment of lymphoproliferative disorders, excluding multiple myeloma. Accordingly to the invention EPO may be administered with a viral or bacterial vaccine.Type: ApplicationFiled: July 12, 2005Publication date: September 25, 2008Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., MOR RESEARCH APPLICATIONS LTD.Inventors: Moshe Mittelman, Drorit Neumann
-
Publication number: 20080233148Abstract: It is intended to provide a safe and efficient method of producing a virus which is free from animal-origin components in the whole process from culturing adhesive cells to producing the virus on an industrial scale by the cell culture. Namely, a method of producing a virus comprising: adhering adhesive cells to a support which has a polypeptide (P) having at least one cell-adhesive minimum amino acid sequence (X) per molecule, and is free from animal-origin components; culturing the adhesive cells in a medium free from animal-origin components; subculturing the cultured adhesive cells using a cell dispersing agent free from animal-origin components; and then inoculating and proliferating a virus in the cells obtained by culturing the adhesive cells.Type: ApplicationFiled: July 19, 2005Publication date: September 25, 2008Applicants: Denka Seiken Co., Ltd., Sanyo Chemical Industries, Ltd.Inventors: Hikaru Kai, Masayuki Tsubaki, Masato Kurokawa
-
Publication number: 20080226676Abstract: The present invention provides vaccine compositions comprising at least two strains of avian influenza virus, wherein one of the strains has an H5 hemagglutinin subtype and the other strain has an H7 hemagglutinin subtype, and wherein at least one of the strains has an N4 neuraminidase subtype and neither strain has an N1 subtype. Also provided are vaccination methods that utilize the novel vaccine compositions of the invention. The compositions and methods of the present invention provide protection against infection with H5 and H7 influenza strains (e.g., H5N1 and H7N1) while at the same time facilitating the distinction between infected and vaccinated animals.Type: ApplicationFiled: March 14, 2008Publication date: September 18, 2008Applicant: WyethInventors: Joan Plana Duran, Mahesh Kumar
-
Patent number: 7425336Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: GrantFiled: November 1, 2005Date of Patent: September 16, 2008Assignee: Mevial LimitedInventors: Jules Maarten Minke, Kemal Karaca, Jiansheng Yao
-
Publication number: 20080213309Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.Type: ApplicationFiled: May 6, 2008Publication date: September 4, 2008Applicant: ALPHVAX, INC.Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
-
Publication number: 20080213308Abstract: The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).Type: ApplicationFiled: September 14, 2005Publication date: September 4, 2008Inventors: Nicholas Valiante, Feng Xu, Xiaodong Lin, Daniel Chu, Xiaojing Michael Wang
-
Publication number: 20080206280Abstract: The invention provides compositions and methods for treating or preventing a target disease in a mammal by induction of memory T cells. The methods comprise (1) administering a sensitizing composition comprising a non-target antigen to a patient; and (2) administering a therapeutic composition comprising a non-target antigen and a target antigen to the patient, wherein the target antigen is associated with the disease, and wherein the therapeutic composition is administered after the sensitizing compositions, at an interval sufficient for induction of memory T cells. The methods can alternatively comprise administering a target antigen along with an inhibitory agent such as an inhibitor of DC apoptosis, an inhibitor of granzyme B, a Granzyme-B-inducible mediator of apoptosis, an inhibitor of perforin, or a perforin-inducible mediator of apoptosis.Type: ApplicationFiled: February 26, 2008Publication date: August 28, 2008Applicant: University of Pittsburgh- Of the Commonwealth System of Higher EducationInventor: Pawel Kalinski
-
Publication number: 20080206278Abstract: Provided herein are methods for immunizing children under six months of age by administering to the child a pharmaceutical composition comprising at least one antigen derived from an influenza virus.Type: ApplicationFiled: October 12, 2007Publication date: August 28, 2008Inventor: Michael Decker
-
Publication number: 20080199495Abstract: The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system. In one embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In one embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: May 24, 2007Publication date: August 21, 2008Applicant: Monash UniversityInventor: Richard L. Boyd
-
Publication number: 20080193412Abstract: A method for enhancing the immune response to an antigen or vaccine comprising administering an effective amount of a Th1 stimulatory cytokine, preferably interferon, oromucosally at substantially the same time as administration of an effective amount of an antigen or vaccine.Type: ApplicationFiled: June 13, 2005Publication date: August 14, 2008Applicant: PHARMA PACIFIC PTY LTD.Inventor: Michael Tovey
-
Patent number: 7411058Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.Type: GrantFiled: July 7, 2006Date of Patent: August 12, 2008Assignee: The University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Patricia W. Dowling, Julius S. Youngner
-
Publication number: 20080187546Abstract: The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce a tissue-culture adapted viral isolate. The invention also includes vaccines produced from the isolate.Type: ApplicationFiled: December 14, 2007Publication date: August 7, 2008Inventors: Terri L. Wasmoen, Peng Gao, Bradley Allen Eddy, Omar Yousif Abdelmagid
-
Publication number: 20080181914Abstract: An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilised in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus preparation may comprise a micelle modifying excipient, for example ?-tocopherol or a derivative thereof in a sufficient amount to stabilise the haemagglutinin.Type: ApplicationFiled: October 18, 2007Publication date: July 31, 2008Inventor: Uwe Eichhorn
-
Publication number: 20080175863Abstract: In certain aspects, the present invention provides methods for increasing the replication capacity of influenza viruses in hens' eggs and/or cell culture, recombinant and/or reassortant influenza viruses with increased replication capacity, and immunogenic and vaccine compositions comprising such recombinant and/or reassortant influenza viruses. In other aspects, the invention further provides nucleic acids encoding influenza genes associated with increased replication capacity, expression vectors comprising the nucleic acids of the invention, methods for making influenza viruses with increased replication capacity, and kits useful for practice of the methods.Type: ApplicationFiled: July 20, 2007Publication date: July 24, 2008Applicant: Medimmune Vaccines, Inc.Inventors: Hong Jin, Bin Liu
-
Publication number: 20080171063Abstract: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant.Type: ApplicationFiled: March 21, 2006Publication date: July 17, 2008Inventors: Emmanuel Jules Hanon, Jean Stephenne
-
Patent number: 7399477Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.Type: GrantFiled: January 23, 2007Date of Patent: July 15, 2008Assignee: The University of Pittsburgh-of the Commonwealth System of Higher EducationInventors: Patricia W. Dowling, Julius S. Youngner
-
Publication number: 20080166348Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.Type: ApplicationFiled: April 10, 2007Publication date: July 10, 2008Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez, Gerd R. Burmester, Philip Mease, Daniel J. Lovell, Edward Keystone, Arthur Kavanaugh
-
Publication number: 20080145383Abstract: Described is a method for making a pharmaceutical preparation comprising the solubilisation of a peptide mixture, characterized in that the peptide mixture is solubilized by an aqueous solution containing at least one organic acid selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid and halogenated or hydroxylated forms thereof.Type: ApplicationFiled: March 11, 2005Publication date: June 19, 2008Applicant: Intercell AGInventors: Wolfgang Zauner, Constantia Kritsch, Christa Heinrich-Cseh, Agnes Berger
-
Patent number: 7384642Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: GrantFiled: August 25, 2005Date of Patent: June 10, 2008Assignee: Merial LimitedInventors: Jules Maarten Minke, Kemal Karaca, Jiansheng Yao
-
Publication number: 20080118531Abstract: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.Type: ApplicationFiled: April 18, 2007Publication date: May 22, 2008Applicants: Wyeth, St. Jude Children's Research HospitalInventors: Erich Hoffmann, Scott L. Krauss, Mahesh Kumar, Richard J. Webby, Robert G. Webster
-
Publication number: 20080112972Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.Type: ApplicationFiled: September 12, 2006Publication date: May 15, 2008Inventor: Vu Truong-Le
-
Publication number: 20080107687Abstract: The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against avian influenza.Type: ApplicationFiled: June 22, 2007Publication date: May 8, 2008Inventor: Herve Poulet
-
Patent number: 7354706Abstract: The invention provides methods to detect molecular recognition events. The invention also provides methods to detect the presence of or identify a target species based on its interaction with one or more probe species. The methods of the invention are based on amplification of the signal due to each molecular recognition event. The amplification is achieved through photopolymerization, with the polymer formed being associated with the molecular recognition event. In an embodiment, a fluorescent polymer, a magnetic polymer, a radioactive polymer or an electrically conducting polymer can form the basis of detection and amplification. In another embodiment, a polymer gel swollen with a fluorescent solution, a magnetic solution, a radioactive solution or an electrically conducting solution can form the basis of detection and amplification. In another embodiment, sufficient polymer forms to be detectable by visual inspection.Type: GrantFiled: March 9, 2006Date of Patent: April 8, 2008Assignee: The Regents of The University of Colorado, a body corporateInventors: Kathy L. Rowlen, John W. Birks, Christopher Bowman, Hadley Sikes, Ryan Hansen, Robert Kuchta
-
Publication number: 20080075736Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: ApplicationFiled: October 19, 2006Publication date: March 27, 2008Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox
-
Patent number: 7344722Abstract: The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously published sequences for cold-adapted A/Ann Arbor/6/60 genes. The cold-adapted live influenza virus of the present invention can be reassorted with a variety of epidemic wild type influenza viruses and used to produce vaccines to prophylactically and therapeutically treat influenza.Type: GrantFiled: December 14, 1995Date of Patent: March 18, 2008Assignee: The Regents of the University of MichiganInventors: Hunein F. Maassab, Martha Louise Herlocher
-
Patent number: 7339037Abstract: The invention provides a method of inhibiting prophylactically or therapeutically an influenza viral infection in a host. The method comprises instilling into or onto a host a cell producing an antiviral protein, antiviral peptide, or antiviral conjugate comprising at least nine contiguous amino acids of SEQ ID NO: 2, wherein the at least nine contiguous amino acids are nonglycosylated and have antiviral activity, whereupon the influenza viral infection is inhibited.Type: GrantFiled: May 28, 2004Date of Patent: March 4, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael R. Boyd, Barry R. O'Keefe, Toshiyuki Mori, Angela M. Gronenborn
-
Publication number: 20080014217Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.Type: ApplicationFiled: March 28, 2007Publication date: January 17, 2008Inventors: Emmanuel Jules Hanon, Jean Stephenne